{
    "clinical_study": {
        "@rank": "6777", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who\n      have recurrent or progressive malignant glioma."
        }, 
        "brief_title": "Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma", 
        "condition": "Brain and Central Nervous System Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Nervous System Neoplasms", 
                "Central Nervous System Neoplasms", 
                "Glioma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the progression-free survival and response rate of patients with recurrent or\n           progressive malignant glioma treated with temozolomide.\n\n        -  Determine whether certain categories of malignant gliomas, such as oligodendroglioma,\n           are more sensitive to temozolomide.\n\n        -  Determine the toxicity of this regimen in these patients.\n\n      OUTLINE: Patients are stratified according to histologic categories (recurrent glioblastoma\n      multiforme [closed to accrual 11/30/01] vs recurrent anaplastic astrocytoma vs recurrent\n      anaplastic oligodendroglioma).\n\n      Patients receive oral temozolomide twice daily for 5 consecutive days. Courses repeat every\n      28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven recurrent or progressive malignant glioma of one of the\n             following types:\n\n               -  Anaplastic oligodendroglioma or oligoastrocytoma\n\n               -  Anaplastic astrocytoma\n\n               -  Glioblastoma multiforme (stratum closed to accrual 11/30/01)\n\n          -  Patients who have failed radiotherapy are eligible\n\n          -  Measurable disease by CT scan or MRI\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 70-100%\n\n        Life expectancy:\n\n          -  At least 12 weeks\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count greater than 1,500/mm^3\n\n          -  Platelet count greater than 100,000/mm^3\n\n          -  Hemoglobin greater than 10 g/dL\n\n        Hepatic:\n\n          -  SGOT or SGPT less than 3 times upper limit of normal (ULN)\n\n          -  Alkaline phosphatase less than 2 times ULN (if greater than 2 times ULN then a gamma\n             glutamyl transferase test must be performed)\n\n        Renal:\n\n          -  BUN less than 1.5 times ULN\n\n          -  Creatinine less than 1.5 times ULN\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective barrier contraception\n\n          -  No other serious concurrent infection or other medical illness that would preclude\n             study entry\n\n          -  No frequent vomiting or partial bowel obstruction\n\n          -  HIV negative\n\n          -  No AIDS-related illness\n\n          -  No other concurrent malignancy except carcinoma in situ of the cervix or basal cell\n             skin cancer\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No concurrent epoetin alfa\n\n        Chemotherapy:\n\n          -  At least 6 weeks since other prior chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 3 months since prior radiotherapy (exceptions allowed for\n             recurrent/progressive disease at discretion of primary investigator)\n\n        Surgery:\n\n          -  Recovered from prior surgery\n\n        Other:\n\n          -  No other concurrent investigational agents\n\n          -  Concurrent anticonvulsant therapy allowed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "January 21, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004204", 
            "org_study_id": "CDR0000067449", 
            "secondary_id": [
                "CPMC-IRB-8622", 
                "SPRI-CPMC-IRB-8622"
            ]
        }, 
        "intervention": {
            "intervention_name": "temozolomide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Temozolomide", 
                "Dacarbazine"
            ]
        }, 
        "keyword": [
            "recurrent adult brain tumor", 
            "adult anaplastic astrocytoma", 
            "adult anaplastic oligodendroglioma"
        ], 
        "lastchanged_date": "January 3, 2014", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CPMC-IRB-8622"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305-5408"
                    }, 
                    "name": "Stanford University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33140"
                    }, 
                    "name": "Mount Sinai Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611-3013"
                    }, 
                    "name": "Robert H. Lurie Comprehensive Cancer Center, Northwestern University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albany", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "12208"
                    }, 
                    "name": "Cancer Center of Albany Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Herbert Irving Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Staten Island", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10305"
                    }, 
                    "name": "Nalitt Institute for Cancer And Blood Related Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Taussig Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Neurological Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104-4283"
                    }, 
                    "name": "University of Pennsylvania Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Froedtert Memorial Lutheran Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study of Temozolomide in the Treatment of Recurrent Malignant Gliomas", 
        "overall_official": {
            "affiliation": "Herbert Irving Comprehensive Cancer Center", 
            "last_name": "Casilda Balmaceda, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004204"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Herbert Irving Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2006"
    }, 
    "geocoordinates": {
        "Cancer Center of Albany Medical Center": "42.653 -73.756", 
        "Cleveland Clinic Taussig Cancer Center": "41.499 -81.695", 
        "Froedtert Memorial Lutheran Hospital": "43.039 -87.906", 
        "Herbert Irving Comprehensive Cancer Center": "40.714 -74.006", 
        "Mount Sinai Comprehensive Cancer Center": "25.791 -80.13", 
        "Nalitt Institute for Cancer And Blood Related Diseases": "40.58 -74.15", 
        "Neurological Clinic": "45.523 -122.676", 
        "Robert H. Lurie Comprehensive Cancer Center, Northwestern University": "41.878 -87.63", 
        "Stanford University Medical Center": "37.429 -122.169", 
        "University of Pennsylvania Cancer Center": "39.952 -75.164"
    }
}